Besilesomab (trade name Scintimun) is a mouse monoclonal antibody labelled with the radioactive isotope technetium-99m. It is used to detect inflammatory lesions and metastases.[1] It binds to an immunoglobulin, IgG1 isotype. SCINTIMUN has been used since 1992 mainly in Hungary, Czech Republic, and Switzerland on the basis of local marketing authorizations, and in Germany (on the basis of individual prescription). Between 1992 and 2009, an estimated 90,000 patients has been studied. In 2009, the EMEA has approved SCINTIMUN for marketing in all European countries.[2][3]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | CEA-related antigen |
| Clinical data | |
| Trade names | Scintimun |
| License data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
  (what is this?) (verify) | |
References
edit- ^ Dübel S, Reichert JM (2014). "76.4.1: Besilesomab". Handbook of Therapeutic Antibodies (2nd ed.). Weinheim, Germany: John Wiley & Sons. p. 2131. ISBN 978-3-527-32937-3.
- ^ "International Nonproprietary Names for Pharmaceutical Substances (INN) Recommended INN: List 54" (PDF). WHO Drug Information. 19 (3): 248. 2005. Archived from the original (PDF) on 16 October 2009.
- ^ "Positive opinion of the CHMP for SCINTIMUN (Besilesomab)" (PDF). European Medicines Agency. 22 October 2009. Archived from the original (PDF) on December 25, 2009.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |